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Abstract
Background: We recently described that HIV latent infection can be established in vitro following incubation of
resting CD4+ T-cells with chemokines that bind to CCR7. The main aim of this study was to fully define the post-
integration blocks to virus replication in this model of CCL19-induced HIV latency.
Results: High levels of integrated HIV DNA but low production of reverse transcriptase (RT) was found in CCL19-treated
CD4+ T-cells infected with either wild type (WT) NL4.3 or single round envelope deleted NL4.3 pseudotyped virus
(NL4.3- Δenv). Supernatants from CCL19-treated cells infected with either WT NL4.3 or NL4.3- Δenv did not induce
luciferase expression in TZM-bl cells, and there was no expression of intracellular p24. Following infection of CCL19-
treated CD4+ T-cells with NL4.3 with enhanced green fluorescent protein (EGFP) inserted into the nef open reading
frame (NL4.3- Δnef-EGFP), there was no EGFP expression detected. These data are consistent with non-productive latent
infection of CCL19-treated infected CD4+ T-cells. Treatment of cells with phytohemagluttinin (PHA)/IL-2 or CCL19, prior
to infection with WT NL4.3, resulted in a mean fold change in unspliced (US) RNA at day 4 compared to day 0 of 21.2
and 1.1 respectively (p = 0.01; n = 5), and the mean expression of multiply spliced (MS) RNA was 56,000, and 5,000
copies/million cells respectively (p = 0.01; n = 5). In CCL19-treated infected CD4+ T-cells, MS-RNA was detected in the
nucleus and not in the cytoplasm; in contrast to PHA/IL-2 activated infected cells where MS RNA was detected in both.
Virus could be recovered from CCL19-treated infected CD4+ T-cells following mitogen stimulation (with PHA and
phorbyl myristate acetate (PMA)) as well as TNFa, IL-7, prostratin and vorinostat.
Conclusions: In this model of CCL19-induced HIV latency, we demonstrate HIV integration without spontaneous
production of infectious virus, detection of MS RNA in the nucleus only, and the induction of virus production with
multiple activating stimuli. These data are consistent with ex vivo findings from latently infected CD4+ T-cells from
patients on combination antiretroviral therapy, and therefore provide further support of this model as an excellent
in vitro model of HIV latency.
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Background
Long-lived latently infected resting memory CD4+ T-cells
persist in patients on suppressive combination antiretro-
viral therapy (cART) and are thought to be the major bar-
rier to curing HIV infection [1-5]. Given the low
frequency of latently infected memory CD4+ T-cells in
vivo [5-9], robust in vitro models of HIV latency in
primary CD4+ T-cells are urgently needed to better
understand the establishment and maintenance of latency
as well as identify novel strategies to reverse latent infec-
tion (reviewed in [10]).
We have previously demonstrated that latent infection
can be established in resting memory CD4+ T-cells in
vitro following incubation with the chemokines CCL19
and CCL21 (ligands for CCR7), CXCL9 and CXCL10
(ligands for CXCR3) and CCL20 (ligand for CCR6)
[11,12]. These chemokines are important for T-cell
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[13-15], and we have proposed that the addition of
chemokines in vitro to resting CD4+ T-cells may model
chemokine rich micro-enviro n m e n t ss u c ha sl y m p h o i d
tissue [11,16]. This model of chemokine-induced HIV
latency is highly reproducible, leading to consistent high
rates of HIV integration, limited viral production and no
T-cell activation [11,12]; and it therefore provides a tract-
able model to dissect the pathways of how latency is
established and maintained in resting CD4+ T-cells.
Latently infected resting CD4+ T-cells are significantly
enriched in tissues such as the gastrointestinal (GI) tract
[17,18] and lymphoid tissue [19]. Ex vivo analysis of these
cells has demonstrated that despite detection of integrated
HIV, spontaneous virus production does not occur [20].
There are multiple blocks to productive infection in
infected resting CD4+ T-cells from patients on cART,
including a block in initiation and completion of HIV
transcription as well as a block in translation of viral pro-
teins by the expression of microRNAs (reviewed in [21]].
In addition, a clear block in export of multiply spliced
(MS) RNA from the nucleus to the cytoplasm has been
demonstrated [22]. Infectious virus can be induced from
resting CD4+ T-cells from patients on cART following sti-
mulation ex vivo with mitogens such as phytohemaglutin-
nin (PHA) or phorbol myristate acetate (PMA); T-cell
receptor activation using anti-CD3 and anti-CD28 [1,2]; or
other stimuli such as IL-7 [23], IL-2 [23], the protein
kinase C (PKC) activator prostratin [24,25], histone deace-
tylase inhibitors (HDACi) such as vorinostat [26,27],
methylation inhibitors [28,29] or a combination of these
approaches [25]. Ideally, reactivation of virus from in vitro
models of HIV latency should also closely mimic ex vivo
findings from patient derived CD4+ T-cells.
The main aim of this study was to examine whether
there was any spontaneous viral production in our chemo-
kine-derived model of latency, to identify the point in the
virus life cycle where virus expression was restricted, and
to identify activation strategies that induce virus produc-
tion from these latently infected CD4+ T-cells. Our results
demonstrated that there was no production of infectious
virus in this in vitro model of HIV latency, and that the
block to productive infection and response to activating
stimuli closely mimic findings from latently infected CD4+
T-cells from patients on cART.
Results
Latency is established in CCL19-treated CD4+ T-cells
following single round infection, and there is no evidence
of spontaneous productive infection
We infected CCL19-treated CD4+ T-cells with WT
NL4.3 and NL4.3Δenv to determine if spreading infection
contributed to the high levels of integrated HIV observed
following infection of CCL19-treated CD4+ T-cells.
Consistent with our previous work [11,12], incubation of
resting CD4+ T-cells with CCL19 followed by infection
with WT NL4.3 resulted in high levels of viral integration
and minimal production of RT in the supernatant,
consistent with latent infection (Figure 1B and 1C). Infec-
tion with NL4.3Δenv also resulted in high levels of viral
integration with levels similar to that observed following
infection with WT NL4.3 (Figure 1B and 1C). As
expected, infection of IL-2/PHA activated cells with
NL4.3Δenv led to reduced RT production and a 10 fold
reduction in integrated HIV. Integration of HIV was not
observed following infection of unactivated resting CD4+
T-cells with either NL4.3 or NL4.3Δenv (Figure 1B and
1C). These data demonstrate that multiple rounds of
infection did not contribute to high levels of integration
observed in CCL19-treated infected CD4+ T-cells.
To determine if there was production of any infectious
virus in CCL19-treated infected CD4+ T-cells, we
infected cells with either WT NL4.3 or NL4.3Δenv (as
described in Figure 1A) and collected supernatants at day
4 following infection. We then cultured these superna-
tants with the indicator cell line TZM-bl and assessed
luciferase activity. Only the supernatant derived from IL-
2/PHA activated CD4+ T-cells infected with WT NL4.3
led to an increase in luciferase activity consistent with
production of infectious virus in these fully activated
CD4+ T-cells (Figure 1D). No infectious virus was
detected in supernatants from CCL19-treated or unacti-
vated CD4+ T-cells infected with either WT NL4.3 or
NL4.3Δenv (Figure 1D).
The absence of productive infection was further con-
firmed by staining for intracellular p24 expression where
we found that CCL19-treated infected CD4+ T-cells
resulted in <1% p24-positive cells in contrast to IL-2/PHA
activated infected CD4+ T-cells (mean p24 expression ~6-
9%; n = 2; Figure 2A). Finally, following infection with
NL4.3Δnef/EGFP of CCL19-treated and IL-2-PHA acti-
vated CD4+ T-cells, EGFP expression was 0% and 2%
respectively (n = 1; Figure 2B).
Taken together, these experiments clearly demon-
strated that in the presence of high levels of HIV integra-
tion in CCL19-treated infected CD4+ T-cells, there was
no production of infectious virus as measured by infectiv-
ity of supernatants, p24 production or EGFP production
consistent with latent infection.
High level of MS RNA but low levels of US RNA in latently
infected CCL19-treated CD4+ T-cells
To identify the point in the virus life cycle following HIV
integration where virus expression was restricted in this
model of CCL19-induced HIV latency, we next examined
expression of US and MS RNA (location of primers are
summarised in Figure 3A). The mean fold increase of US
RNA (expression at day 4 compared to day 0) following
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unactivated CD4+ T-cells was 21.1, 1.1 and 0.5 fold
respectively (n = 5; p < 0.05 for all comparisons; Figure
3B). We measured the fold change in US RNA in these
experiments because US RNA was always detected at
baseline i.e. immediately following virus removal by
washing (average 3,700 copies/million cells in all condi-
tions) which we assumed was US RNA in the viral inocu-
lums that had adhered to the surface or was endocytosed
in the CD4+ T-cells. When we adjusted for the amount
of integrated HIV DNA in the same experiment for each
condition, the mean US RNA: integrated DNA ratio was
0.25 and 0.08 for PHA/IL-2 activated and CCL19-treated
infected CD4+ T-cells respectively (n = 5).
T h em e a nc o p yn u m b e ro fM SR N Ai nI L - 2 / P H A
activated, CCL19-treated and unactivated CD4+ T-cells
infected with WT NL4.3 was 56,000, 5,000 and <200
copies/million cells respectively (n = 5; Figure 3B). The
levels of MS RNA were not significantly different
between the IL-2/PHA and CCL19 activated cells (P=
0.055). However, MS RNA was significantly higher in
both infected IL-2/PHA and CCL19 treated cells when
compared to unactivated cells (P =0 . 0 1 ) .W h e nw e
adjusted for the amount of integrated HIV DNA in the
same experiment, the mean MS RNA: integrated DNA
ratio was 0.1 and 0.6 for PHA/IL-2 activated and
CCL19-treated infected CD4+ T-cells respectively (n =
5; Figure 3). We also examined production of 4 kb sin-
gly spliced (SS) RNA (primers 0dp 2137 Universal for-
ward and 0dp 2139 reverse; Figure 3A) and found high
level expression in IL-2/PHA activated infected CD4+
T-cells, and low levels in CCL19-treated infected CD4+
T-cells while SS RNA was not detected in unactivated
CD4+ T-cells (data not shown). Using a different set of
primers to measure US and MS RNA (0dp 2137, 0dp
2138, 0dp 2139, and 0dp2140, Table 1) with two differ-
ent donors, we further confirmed our findings of no
production of US RNA but high level production of MS
RNA in CCL19-treated infected CD4+ T-cells (data not
shown).
To further determine why MS RNA production in
CCL19-treated infected CD4+ T-cells did not lead to effi-
cient expression of US RNA, we examined both US and
MS RNA in cytoplasmic and nuclear fractions from
infected IL-2/PHA activated, CCL19-treated, and unacti-
vated CD4+ T-cells. Both US and MS RNAs were
detected in the cytoplasmic and nuclear fractions in IL-2/
PHA activated infected CD4+ T-cells (Figure 3C). As
expected, US RNA was low in both cytoplasmic and
nuclear fractions in CCL19-treated and unactivated
infected CD4+ T-cells. MS RNA was almost entirely loca-
lized to the nucleus in CCL19-treated infected CD4+ T-
cells, and was not detected in either fraction in unacti-
vated CD4+ T-cells (Figure 3C and 3D). The ratio of
Figure 1 High levels of HIV integration with minimal virus
production in CCL19-treated infected CD4+ T-cells consistent
with latent infection. (A). Schematic diagram of the experimental
protocol used for isolation of CD4+ T-cells and HIV infection.
Resting CD4+ T-cells were cultured for 2 days with PHA/IL-2, CCL19
or without activation (unactivated). Cells were then infected with
WT NL4.3, NL4.3Δenv or NL4.3-Δnef/EGFP or mock for 2 hrs and
virus was washed off. The infected cells were cultured with media
containing IL-2 (10 IU/mL) for 4 days. Infection of cells with WT
NL4.3 (open bars) or NL4.3Δenv (grey bars) was quantified by
detection of (B) integrated HIV DNA (C) RT activity (CPM/μl) in
culture supernatant or (D) luciferase activity of supernatants using
the TZM-bl indicator cell line. In all graphs, the mean (column) and
individual data (open symbols) from two donors are shown.
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vated and CCL19-treated infected cells was 0.02 and 0.15
respectively (n = 2; Figure 3C and 3D).
Taken together, these data demonstrate that in
CCL19-treated infected CD4+ T-cells, production of MS
RNA occurs, but there is no MS RNA detected in the
cytoplasm, similar to descriptions of resting CD4+ T-
cells from HIV-infected patients on cART [22].
Virus production from latently infected CCL19 stimulated
cells
Finally, we used our model of CCL19-treated latently
infected CD4+ T-cells to determine if cellular activators
and the HDACi vorinostat could induce viral expression
and compared the response to the latently infected T-cell
line ACH2 (Figure 4B). The mean (range) production of
RT (expressed as a percentage of maximal stimulation
with PHA/PMA) following stimulation with TNFa was
38% (32-56%); IL-7 was 43% (35-55%); prostratin was
57% (51-64%); vorinostat was 12% (9-15%) day 7 post
infection (day 3 post stimulation) with higher levels of
RT production by day 10 post-infection following TNFa,
IL-7 and vorinostat, but not following prostratin (n = 4;
Figure 4B). The combination of IL-7 and prostratin,
resulted in the highest levels of RT production (76% (68-
92%)) which in one donor approached that of the maxi-
mal stimulation with PHA/PMA (Figure 4B, inverted tri-
angles). In the ACH2 cell line, all stimuli led to induction
of virus expression except that there was no response to
IL-7 (Figure 4B).
Discussion
We have previously established an in vitro model of HIV
latency following incubation of resting CD4+ T-cells with
the CCR7 ligands, CCL19 [11,12]. We have shown here
that, in this in vitro model of HIV latency, there was no
Figure 2 No productive HIV infection in CCL19-treated infected cells. Resting CD4+ T cells were cultured for 2 days with PHA/IL-2, CCL19 or
without activation (unactivated). Cells were infected with NL4.3 or NL4.3-Δnef/EGFP for 2 hrs. The virus was washed off and the infected cells
were cultured with media containing IL-2 (10 IU/mL) for up to 4 days. Productive infection was detected by flow cytometry of (A) intracellular
HIV p24 (Alexa-488) following infection with NL4.3 (left panels; two representative donors). The right hand panels show the corresponding
integrated copies of HIV per million cells for the same donors (as the mean of two donors (column) and as individual data (open symbols)). (B)
Productive infection was detected by flow cytometry of EGFP expression following infection with NL4.3-Δnef/EGFP (one donor). The integrated
copies of HIV per million cells are shown for this donor (right hand panel). SSC = side scatter.
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Page 4 of 11Figure 3 High level of nuclear MS RNA in CCL19-treated latently infected CD4+ T-cells. (A) Schematic diagram of the broad classes of HIV
mRNA, including multiply spliced (MS) singly spliced (SS) and unspliced (US) HIV RNA (adapted from [56]). Location of primers and probes used
for real-time PCR quantification of US, SS and MS RNA are shown. (B) Resting CD4+ T cells were activated with IL-2/PHA, CCL19 or unactivated
and infected with NL4.3 or NL4.3Δenv. The fold increase in US RNA at day 4 post infection (relative to day 0; left panels) and the absolute copies
per million cells of MS RNA (right panels) is shown for (B) total RNA following infection with WT NL4.3 (n = 5) and (C and D) nuclear (open) and
cytoplasmic (grey) fractions following infection with (C) NL4.3 and (D) NL4.3Δenv. The mean (column) and individual data (open symbols) are
shown. The ratio of MS RNA to integrated DNA for each donor is also shown (C and D, far right panel). The detection limit for US RNA and MS
RNA was 200 copies/10
6 cells and is shown as dashed line for MS RNA. * = P < 0.05.
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block in the virus life cycle and the response to activating
stimuli closely mirrors findings by other groups in ex
vivo resting CD4+ T-cells from HIV-infected patients on
cART [20,22,23,25].
We found that in CCL19-treated latently infected cells
MS RNA was detected in the nucleus, but not in the cyto-
plasm, in contrast to PHA/IL-2 activated infected cells
where MS RNA was detected in both nucleus and cyto-
plasm. MS RNA encodes the positive regulators Rev and
Tat that are crucial for the efficient expression of US RNA
in the cytoplasm [30,31]. Therefore, the lack of US RNA
expression and viral production in CCL19-treated infected
CD4+ T-cells may be explained by the absence of MS
RNA in the cytoplasm. The absence of MS RNA in the
cytoplasm could potentially be secondary to a block in
nuclear export of viral mRNA or destruction of MS RNA
in the cytoplasm. We were unable to distinguish between
these two possibilities; however, others have previously
described that in CD4+ T cells from patients on cART,
there is a block in export of MS RNA to the cytoplasm
secondary to low levels of polypyrimidine tract binding
p r o t e i ni nr e s t i n gC D 4 +T - cells [22]. We have recently
compared gene expression using Illumina microarrays in
resting CD4+ T-cells with and without CCL19 [11], and
found no difference in the expression of PTB in the pre-
sence or absence of CCL19 (data not shown). These data
suggest that PTB may also be functional in this chemokine
model of HIV latency, but further experiments will be
required to demonstrate this directly.
Production of virus from CCL19-treated infected CD4+
T-cells was clearly demonstrated following activation with
multiple different stimuli. The combination of IL-7 and
prostratin resulted in the highest levels of RT production
(Figure 4B). Prostratin stimulates HIV through PKC
-mediated release of active nuclear factor B( N F - B) [24].
Previous studies have shown that inadequate or low
nuclear levels NF-B and nuclear factor of activated T cells
(NFAT) may contribute to the maintenance of latency in
resting CD4+ T-cells (reviewed in [32-34]). IL-7 has been
shown to effectively induce HIV replication ex vivo in both
CD8 depleted PBMCs and resting CD4+ T-cells from
patients on cART [23]. IL-7 can activate both the PI3K and
the STAT 5 pathways which could both potentially
enhance virus transcription [35,36]. Activation of PI3K
could increase virus transcription via enhanced production
of NF-kB [37-39] while phosphorylated STAT5 has been
shown to bind and transactivate viral transcription in ex
vivo primary CD4+ T-cells; in the HeLa cell line co-trans-
fected with STAT5 expression vectors and an HIV LTR
construct that expresses firefly luciferase construct; and in
the latently infected cell line (U1) [34,40,41]
IL-7 may also potentially contribute to the mainte-
n a n c eo fH I Vl a t e n c yv i ah o m e o s t a t i cp r o l i f e r a t i o no f
resting CD4+ T-cells [5], but proliferation alone would
not explain our findings that IL-7 can induce virus pro-
duction from latently infected cells [42]. Furthermore,
we found that IL-7 alone had no effect on T-cell prolif-
eration of purified resting CD4+ memory T-cells which
were used in this model, as measured by Ki67 staining
and dilution of carboxyfluorosceinsuccinate (CFSE)
(data not shown). The exact mechanism of action of IL-
7 in our CCL19-induced model of latency remains
unclear.
Table 1 Names, description and sequences of the primers and probes used for the real-time qPCR for HIV integrated
DNA, US RNA, MS RNA, and SS RNA
Name Description Sequence
MH535 1
st rd forward 3’LTR 5’ -AACTAGGGAACCCACTGCTTAAG-3’
SB407 1
st rd reverse Alu 5’ -TGCTGGGATTACAGGCGTGAG-3’
SL75 2
nd rd forward 5’ -GGAACCCACTGCTTAAGCCTC-3’
SL76 2
nd rd reverse 5’ -GTCTGAGGGATCTCTAGTTACC-3’
SL72 beacon FAM-CGGTCGAGTGCTTCAAGTAGTGTGTGCCCGTC CGACCG-TAMRA-3’
SL19 US forward 5’ - TCTCTAGCAGTGGCGCCCGAACA-3’
SL20 US reverse 5’ - TCTCCTTCTAGCCTCCGCTAGTC-3’
SL30 US beacon 5’ FAM-CGGGAG TACTCACCAGTCGCCGCCCCTCGCC CTCCCG (Dabcyl) 3’
SL28 MS Forward 5’ - CTTAGGCATCTCCTATGGCAGGAA - 3’
SL29 MS reverse 5’ - TTCCTTCGGGCCTGTCGGGTCCC - 3’
SL38 MS RNA beacon 5’ GGGCCT TCTCTATCAAAGCAACCCACCTCC AGGCCC -3’
0dp 2137 Universal forward 5’ CGCACGGCAAGAGGCAGG-3’
0dp 2138 US reverse 5’ CCCGCTTAATACCGACGCTCTCG-3’
0dp 2140 MS reverse 5’ GTCGGGTCCCCTCGGGATTGG-3’
0dp 2139 SS reverse 5’ AGGTTGCATTACATGTACTACTTACTGCTT-3’
LTR = long terminal repeat; US = unspliced HIV RNA; MS = multiply spliced HIV RNA; SS = singly spliced HIV RNA
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Page 6 of 11Figure 4 Virus production from latently infected CCL19 stimulated cells. (A) Schematic diagram of the experimental protocol used for
infection and restimulation of CCL19-treated resting CD4+ T-cells. Resting CD4+ T-cells were cultured for 2 days with CCL19 and infected with
NL4.8 and then restimulated with different activation agents at day 4 post- infection (PI). PHA-stimulated activated PBMCs were added at a ratio
of 2:1. The cultures were maintained in IL-2 alone. Supernatant was harvested at day 7 and 10 PI to detect RT activity. (B) RT activity (CPM/μl)
was measured following incubation of CCL19-treated infected CD4+ T-cells with (i) PHA/PMA (maximal stimulation) or with DMSO, (ii) TNFa, IL-7,
prostratin and the combination of IL-7 with prostratin (expressed as percentage of maximal stimulation), (iii) PHA/PMA or DMSO (from different
donors for vorinostat (SAHA) experiments) or (iv) vorionostat (SAHA) expressed as percentage of maximal stimulation (from (iii)). The mean
(column) and individual data (open symbols) from four donors are shown. (C) The latently infected cell line ACH2 was also incubated with the
same stimuli as in (B) and supernatant collected at day 1, 2 and 3 post stimulation. The mean (column) and individual data (open symbols) from
three separate experiments, following activation with vorinostat (SAHA) are shown.
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our model which is consistent with findings in latently
infected primary CD4+T cells that were transduced with
the prosurvival molecule Bcl-2 [43] and in multiple
latently infected cell lines [44,45]. In contrast, in another
primary latency model using non-polarised cells that
were activated, infected and allowed to rest, TNFa did
not result in any virus reactivation [6]. In these two pre-
vious studies using primary T-cell models of latency, a
similar concentration of TNFa, 10 ng/ml, was used as
we have used in this study although the response rates
were quite different with a percent maximal stimulation
of 40%, 20% and 0% in our, the Yang [43] and Bosque
[6] models respectively. The differences in detection of
reactivation are unlikely to be explained by the fre-
quency of latently infected cells as in our model of che-
mokine induced latency, on average 1% of cells contain
integrated DNA, which is similar to the Yang model
[43] but is far lower than the frequency of latently
infected cells using the Bosque model, where the fre-
quency of latently infected cells approached 30-50% [6].
To our knowledge, reactivation of latent infection with
TNF-a has not been assessed inr e s t i n gC D 4 +T - c e l l s
from patients on suppressive cART and these experi-
ments would add further insight to our understanding
of the currently available different models of latency in
primary T-cells.
Others have demonstrated the synergism obtained by
treatment with a combination of prostratin and the
HDACi vorinostat in both a cell line and primary cell
model of latent HIV infection [46]. Herein we also demon-
strated the additive effects in activation of HIV replication
by combining the PKC activator prostratin with IL-7. We
have not yet evaluated the effects of IL-7 with other
HDACi in this model, but this will certainly be of interest
given the well known safety profiles of drugs such as IL-7
and vorinostat. Strategies that activate latent HIV in
infected individuals on cART are likely to include combi-
natorial approaches and our model provides a robust tool
for screening such approaches.
Conclusions
In this model of CCL19-induced HIV latency, we
demonstrated highly efficient integration of HIV and no
spontaneous production of infectious virus. MS RNA
was produced, but was not detected in the cytoplasm
consistent with findings from resting CD4+ T cells from
patients on cART. Furthermore, virus could be activated
using multiple different stimuli previously shown to acti-
vate virus production ex vivo from resting CD4+ T-cells
from patients on cART. These data provide further sup-
port to this model as an excellent in vitro model to
s t u d yH I Vl a t e n c ya n dau s e f u lt o o lt os c r e e nf o rn o v e l
compounds to reverse latency.
Methods
Isolation of CD4+ T cells
Peripheral blood mononuclear cells (PBMC) were iso-
lated from buffy coats obtained from the Australian Red
Cross Blood Service (Southbank, Australia). Resting
CD4+ T cells were isolated by magnetic bead depletion
and cell sorting using a cocktail of antibodies to CD19,
CD11b, CD14, HLA-DR, CD16 and CD69, as previously
described [11,12]. The purity of resting CD4+ T cells
was routinely >95% when assessed by flow cytometry.
HIV Plasmids, transfection, and infection
HIV infection was performed with either the CXCR4-
using wild type (WT) virus NL4.3 or NL4.3 with enhanced
green fluorescent protein (EGFP), inserted into the nef
open reading frame [NL4.3-Δn e f / E G F P ]a ta m i n oa c i d
position 75 at the aKpnI (Acc651) site (kindly provided by
Damian Purcell, University of Melbourne, Melbourne,
Australia) or envelope deleted NL4.3 pseudotyped virus
(NL4.3-Δenv). 293T cells were transfected with the plas-
mids for NL4.3 or NL4.3-Δnef/EGFP according to the
manufacturer’s instructions (FuGene; Roche Diagnostics,
Indianapolis, IN). NL4.3-Δenv was generated by co-trans-
fection of 293T cells with plasmid DNA encoding a dele-
tion from bp 6343 to bp 7611 in env (kindly provided by
Damian Purcell), and the SVIII plasmid containing the env
of NL4.3 [47] (kindly supplied by M Churchill, Burnet
Institute, Melbourne, Australia). Culture supernatants
containing each of the above viruses were concentrated
over 20% sucrose gradients and assessed for reverse tran-
scriptase (RT) activity as previously described [48].
Purified resting CD4+ T-cells were incubated with the
chemokine CCL19 at 29 nM (R&D Minneapolis, MN),
PHA (10 μg/ml; Sigma, St Louis, MO) combined with IL-2
(10 IU/ml, Roche, Indianapolis, IN) or left unactivated for
two days before HIV infection. Infection was performed
with virus at a concentration of 1 count per minute
(CPM) per cell for 2 hr at 37°C. The cells were then
washed and cultured in the presence of IL-2 (10 IU/ml) as
previously described [11,12]. The method used for infec-
tion of resting CD4+ T-cells is summarised in Figure 1A.
RNA and DNA extraction
Whole cells were lysed in Trizol (Invitrogen) and total
RNA extracted according to the manufacturer’s instruc-
tions (RNeasy Mini Kit, Qiagen). Nuclear and cytoplas-
mic RNAs were obtained as previously described [22].
Genomic DNA was extracted from infected cells using
the DNeasy DNA extraction kit (Qiagen) according to
the manufacturer’s instructions.
Quantification of HIV infection
Production of HIV was quantified by measuring the
Reverse Transcriptase activity in cell culture supernatant
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described [48] as well as by measuring integrated HIV
DNA and RNA at day 4 post-infection using real-time
PCR (iCycler, Bio-Rad, Hercules, CA). Integrated HIV
DNA was quantified using a nested Alu-long terminal
repeat (LTR) PCR as previously described [49,50]. In
brief, we used standards that contained random integra-
tion sites as previously described [51]; all samples were
run in triplicate and we used an additional control reac-
tion that included the LTR primer alone [49,50]. Input
DNA was normalized by quantification of the CCR5
gene by real-time PCR [52]. Detection of unspliced (US)
and multiple spliced (MS) HIV RNA was performed as
previously described [49,53]. To adjust for the total cel-
lular RNA in each sample, relative copy numbers were
normalized to 18S rRNA [49]. The location of all pri-
mers and probes used are summarised in Figure 3A and
Table 1.
Flow cytometry analysis
Expression of EGFP was determined 4 days following
infection using flow cytometry. For analysis of intracel-
lular p24, cells were permeabilized with a mild detergent
and stained with a monoclonal antibody against HIV
p24 followed by detection with Alexa Fluor 488 goat
anti-mouse IgG (H + L, Molecular probes, Eugene, OR)
and samples were analyzed by FACSCalibur flow cyt-
ometer (BD Biosciences) as previously described [6].
Briefly, 1.5 to 2.5 × 10
5 cells were fixed and permeabi-
lized with Cytofix/Cytoperm during 30 minutes at 4°C.
Cells were washed with Perm/Wash Buffer and stained
with a 1:50 dilution of mouse anti-p24 antibody (183) in
100 μL Perm/Wash Buffer during 30 minutes at 4°C.
Cells were washed with Perm/Wash Buffer and incu-
bated with 1:100 Alexa Fluor 488 goat antimouse IgG
(H + L) in 100 μL Perm/Wash Buffer for 30 minutes at
4°C. Cells were washed with Perm/Wash Buffer and
samples were analyzed by flow cytometry. Results were
analyzed using the Weasel Flow cytometry analysis soft-
ware (v2.7, Walter and Elisa Hall Institute, Melbourne,
Australia).
Detection of HIV infection in cell lines
The indicator TZM-bl cell line (obtained through the
AIDS Research and Reference Reagent Program, Divi-
sion of AIDS, NIAID, NIH from Dr. John C. Kappes,
Dr. Xiaoyun Wu and Tranzyme Inc.) is derived from
the HeLa cell line, expresses high levels of CD4, CXCR4
and CCR5 on the cell surface and is stably transfected
with the luciferase and b-galactosidase genes under the
control of the HIV LTR. TZM-bl cells were cultured in
DMEM supplemented with 10% cosmic calf serum
(CCS) and penicillin/streptomycin. Activation of the
HIV LTR was detected using a luciferase assay as
previously described [54]. Briefly, TZM-bl cells were
placed at a concentration of 2 × 10
4 cells/well in 96-well
flat-bottomed tissue culture plates and incubated for 24
h at 37°C, 5% CO2. The culture medium was replaced
by culture medium containing 10μg/μld i e t h y l a m i -
noethyl-dextran (DEAE-dextran), and the cells were
infected with 2-fold serial dilutions of culture superna-
tant from infected primary CD4+ T cells. After 48 h
incubation at 37°C with 5% CO2, the medium was aspi-
rated and 35 μlo fc e l lc u l t u r el y s i sr e a g e n t( P r o m e g a ,
Wisconsin, USA) were added to each well. Five microli-
ters of each sample were mixed with 25 μl of Luciferase
Assay Substrate (Promega), and luminescence was mea-
sured using the FLUOstar OPTIMA multi-detector
reader (BMG Labtech).
Virus production from latently infected cells
To induce virus production, CCL19-treated latently
infected CD4+ T-cells were incubated with PMA (10
nM, Sigma) and PHA (10 μg/mL, Sigma); TNFa (10 ng/
mL, R&D); IL-7 (5 ng/mL, R&D); prostratin (5 μM,
Sigma); a combination of IL-7 and prostratin; or the
HDACi vorinostat (suberoylhydroxamic acid (SAHA);
0.5μM Selleck Chemicals, Houston, TX), on day 4 post-
infection. PHA-activated feeder peripheral blood mono-
nuclear cells (PBMCs) were added 24 h after the activat-
ing stimulus to amplify virus replication so as to
enhance detection of infection. Virus production was
measured in supernatant by quantification of RT pro-
duction on days 7 and 10 post infection (day 3 and 6
following stimulation). The strategy used for activation
is summarized in Figure 4A. The same stimuli were also
used with the latently infected cell line ACH2 [55],
( k i n dg i f tf r o mt h eN a t i o n a lI n s t i t u t e so fH e a l t h( N I H )
Reagents Repository) and supernatants collected at day
1, 2 and 3 post-stimulation. In both latently infected
CCL19-treated cells and in the ACH2 cell line, a combi-
nation of the mitogens PHA and PMA was used to
achieve maximal viral production as measured by RT in
supernatant. The viral production induced by TNFa, IL-
7, prostratin, a combination of IL-7 and prostratin or
vorinostat was then expressed as a percent of the maxi-
mal stimulation.
Statistical analysis
Differences between experimental conditions were ana-
lysed using the Students t-Test or Mann Whitney non-
parametric statistics (Graphpad prism version 3, Graph-
pad, Loa Jolla, CA). p < 0.05 was considered significant.
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